The FDA rejected tab-cel twice. Can Atara’s third review finally deliver approval?
The FDA has accepted Pierre Fabre's resubmitted application for tabelecleucel, setting a March 31, 2027 decision date. The review follows two rejection letters, including a January 2026 dispute over whether the ALLELE study adequately establishes effectiveness.
